Hi Isis - I'm afraid I can't shed much light on the why? aspect of that question. Looked through the Quebec RAMQ formulary, which was updated yesterday and their Sovaldi listing is as follows:
SOFOSBUVIR:
"in association with ribavirin and pegylated interferon alfa, for treatment of persons suffering from chronic hepatitis C genotype 1 or 4, who are not HIV-1 infected and who have never received an anti-HCV treatment;
Authorization is granted for a maximum period of 12 weeks."
So, it would appear it's specific to tx-naive genos 1 and 4, as well as excluding the co-infected . I have no idea how much flexibility Canadian physicians have prescribing alternatively. Hopefully someone else can illuminate things for us.
It really is exciting news that Quebec residents will now have access to Sovaldi, but are they limiting the tx to those who are tx naive, and if so, why?
Isiscat2011 said
Jun 3, 2014
Excellent news! And, tx will be provided regardless of level of fibrosis.
What is this about treatment-naive and GT 1 and 4, though? Are they intending to exclude tx-experienced and other GTs or am I missing something here?
OldenSlow said
Jun 2, 2014
Priority Review by INESSS Provides Recommendation to Treat Patients with Genotypes 1 and 4 HCV Infection Regardless of Fibrosis Level
Montreal, June 2, 2014 /CNW/ - "Gilead Sciences Canada, Inc. is pleased to announce that the Health and Social Services Ministry has placed Sovaldi® (sofosbuvir), the newest treatment for chronic hepatitis C virus (HCV) infection approved for sale in Canada, on the Liste de médicaments (effective June 2, 2014). With this listing, Quebec becomes the first Canadian province to provide access to Sovaldi for treatment-naïve patients with genotypes 1 and 4 HCV infection regardless of liver severity."
Hi Isis - I'm afraid I can't shed much light on the why? aspect of that question. Looked through the Quebec RAMQ formulary, which was updated yesterday and their Sovaldi listing is as follows:
SOFOSBUVIR:
"in association with ribavirin and pegylated interferon alfa, for treatment of persons suffering from chronic hepatitis C genotype 1 or 4, who are not HIV-1 infected and who have never received an anti-HCV treatment;
Authorization is granted for a maximum period of 12 weeks."
So, it would appear it's specific to tx-naive genos 1 and 4, as well as excluding the co-infected . I have no idea how much flexibility Canadian physicians have prescribing alternatively. Hopefully someone else can illuminate things for us.
Formulary Link (large pdf file)
Hi Olden Slow: Just thought I'd bump this up.
It really is exciting news that Quebec residents will now have access to Sovaldi, but are they limiting the tx to those who are tx naive, and if so, why?
Excellent news! And, tx will be provided regardless of level of fibrosis.
What is this about treatment-naive and GT 1 and 4, though? Are they intending to exclude tx-experienced and other GTs or am I missing something here?
Priority Review by INESSS Provides Recommendation to Treat Patients with Genotypes 1 and 4 HCV Infection Regardless of Fibrosis Level
Montreal, June 2, 2014 /CNW/ - "Gilead Sciences Canada, Inc. is pleased to announce that the Health and Social Services Ministry has placed Sovaldi® (sofosbuvir), the newest treatment for chronic hepatitis C virus (HCV) infection approved for sale in Canada, on the Liste de médicaments (effective June 2, 2014). With this listing, Quebec becomes the first Canadian province to provide access to Sovaldi for treatment-naïve patients with genotypes 1 and 4 HCV infection regardless of liver severity."
Full Article
CAPAHC Article